Edition:
United Kingdom

NanoCarrier Co Ltd (4571.T)

4571.T on Tokyo Stock Exchange

1,068JPY
2:29am GMT
Change (% chg)

¥-38 (-3.44%)
Prev Close
¥1,106
Open
¥1,080
Day's High
¥1,118
Day's Low
¥1,024
Volume
3,710,000
Avg. Vol
983,113
52-wk High
¥1,118
52-wk Low
¥618

Chart for

About

NanoCarrier Co., Ltd. is a Japan-based biopharmaceutical products developer. The Company develops biopharmaceutical products focused on the medication of cancer and other intractable diseases. It is engaged in the research, development, manufacture, and sale of anti-cancer drugs based on micellar nanoparticle technology. The... (more)

Overall

Beta: 2.65
Market Cap(Mil.): ¥28,727.59
Shares Outstanding(Mil.): 43.20
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 85.70 16.58
EPS (TTM): -- -- --
ROI: -- 3.19 10.60
ROE: -- 4.52 14.19

BRIEF-NanoCarrier starts to discuss business alliance with Ceolia Pharma

* Says it starts to discuss business alliance with Ceolia Pharma Co., Ltd., and will cooperate on sale, manufacture and development of pharmaceuticals

17 Jan 2018

BRIEF-NanoCarrier signs license preferential negotiating rights agreement with AccuRna

* Says it and AccuRna Inc entered into a preferential negotiating rights agreement on exclusive right to license of drug development based on co's gene delivery technology

04 Dec 2017

BRIEF-VBL Therapeutics and Nanocarrier signs agreement for VB-111 in Japan

* VBL Therapeutics and Nanocarrier Co Ltd sign exclusive agreement for VB-111 in Japan

06 Nov 2017

BRIEF-Nanocarrier signs exclusive agreement with VBL Therapeutics for VB-111 in Japan

* Says co signs an exclusive license agreement with VBL Therapeutics, for the development, commercialization, and supply of ofranergene obadenovec ("VB-111") in Japan

06 Nov 2017

BRIEF-NanoCarrier and JCR conclude collaborative research agreement for drug delivery to the brain for nucleic acid medicines

* Says it and NanoCarrier Co., Ltd conclude collaborative research agreement for drug delivery to the brain for nucleic acid medicines

10 Oct 2017

BRIEF-NanoCarrier says orphan drug designation of NC-6004 by the U.S. FDA

* Says NC-6004, which is under development in the U.S. for biliary cancer, has been granted to the orphan drug designation from the U.S. FDA (Food and Drug Administration)

01 Aug 2017

Earnings vs. Estimates